The combination of the three transcription factors Ascl1, Brn2, and Myt1l has been shown to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells 7 . Ascl1 acts as an 'on-target' pioneer factor to activate the neuronal program, whereas access of Brn2 to the chromatin is context-dependent and facilitates reprogramming later on 8 . Although Ascl1 alone is sufficient to generate iN cells, endogenous Myt1l is induced during reprogramming and exogenous Myt1l greatly improves the efficiency of reprogramming and the functional maturity of the resulting iN cells 9, 10 . To investigate the role of Myt1l in reprogramming, we first raised antibodies specific for mouse and human Myt1l (Extended Data Fig. 1 ). Chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) of endogenous Myt1l in fetal neurons (embryonic day (E) 13.5) and ectopic Myt1l in mouse embryonic fibroblasts (MEFs) two days after induction identified 3,325 high-confidence Myt1l peaks that overlapped remarkably well between neurons and MEFs (Fig. 1a, Extended Data Fig. 2 is significantly enriched at bound sites across datasets. P = 1 × 10 −43 , E = 9.6 × 10 −3 . e, Pie chart indicates enrichment of high-confidence Myt1l-bound sites at gene promoters.
The combination of the three transcription factors Ascl1, Brn2, and Myt1l has been shown to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells 7 . Ascl1 acts as an 'on-target' pioneer factor to activate the neuronal program, whereas access of Brn2 to the chromatin is context-dependent and facilitates reprogramming later on 8 . Although Ascl1 alone is sufficient to generate iN cells, endogenous Myt1l is induced during reprogramming and exogenous Myt1l greatly improves the efficiency of reprogramming and the functional maturity of the resulting iN cells 9, 10 . To investigate the role of Myt1l in reprogramming, we first raised antibodies specific for mouse and human Myt1l (Extended Data Fig. 1 ). Chromatin immunoprecipitation followed by DNA sequencing (ChIP-seq) of endogenous Myt1l in fetal neurons (embryonic day (E) 13.5) and ectopic Myt1l in mouse embryonic fibroblasts (MEFs) two days after induction identified 3,325 high-confidence Myt1l peaks that overlapped remarkably well between neurons and MEFs ( Table 1) . Thus, similar to the pioneer factor Ascl1, Myt1l can access the majority of its cognate DNA binding sites even in a distantly related cell type. However, unlike Ascl1 targets 8 , the chromatin at Myt1l targets is preferentially open (nucleosome-free) in fibroblasts (Fig. 1b) .
Hence, Myt1l appears to possess no pioneer factor activity, raising the question why the targets of a neuron-specific transcription factor are easily accessible in fibroblasts. As expected, there was little overlap between the target sites of Myt1l and Ascl1, and the chromatin binding of Myt1l was not strongly affected by Ascl1 and Brn2, indicating that these factors bind and function independent from each other (Fig. 1c, Extended  Data Fig. 2d ). Conversely, Brn2 targets were co-enriched for both Ascl1 and Myt1l, suggesting that access of Brn2 to chromatin in fibroblasts is strongly directed by other factors 8 (Extended Data Fig. 2d ). De novo motif discovery identified an AAGTT motif that was significantly enriched in all Myt1l ChIP-seq experiments (Fig. 1d) , which is similar to a previously proposed motif 11, 12 . Remarkably, almost half of the Myt1l peaks were located in gene promoters, allowing us to associate them with likely target genes (Fig. 1e) . Accordingly, we found histone marks associated with active promoters, such as H3K27ac and H3K4me3 enriched at Myt1l-bound regions in MEFs (Extended Data Fig. 2e) .
We next assessed the transcriptional effects of Myt1l by RNA sequencing (RNA-seq) 8 ( Fig. 2a, Extended Data Fig. 3 , Supplementary Table 2 ). On average, Myt1l targets were significantly downregulated in reprogramming fibroblasts, indicating that Myt1l may be a transcriptional repressor that functions to silence the fibroblast program during reprogramming. Indeed, gene set enrichment analysis (GSEA) showed significant enrichment of MEF signature genes among the repressed Myt1l target genes (Fig. 2b, Supplementary Table 3 ). To functionally evaluate whether the repressive or activating properties of Myt1l drive iN cell reprogramming, we fused activating (VP64) or repressing (engrailed repressor; EnR) domains to a putative DNAbinding fragment of Myt1l (410-623). The VP64-Myt1l fusion had a strong dominant-negative effect on Ascl1-mediated neuronal conversion, whereas the EnR-Myt1l fusion significantly increased the number of cells expressing the neuron-specific class III β -tubulin TUJ1 and Tau-eGFP compared to the inactive Myt1l fragment (410-623) (Fig. 2d, e) . Thus, transcriptional repression is the predominant function of Myt1l during neuronal reprogramming. We then investigated whether the role of Myt1l might go beyond repressing the fibroblast identity. We found many Myt1l target genes with prominent non-neuronal developmental roles, and most of these genes were downregulated or remained silent during reprogramming (Fig. 2c) . Among the repressed targets were negative regulators of neurogenesis (Notch and Wnt pathway members, as well as Id3), key effectors of proliferation (such as Jak/Stat, Hippo, transforming growth factor (TGF) and Shh signalling pathway members), and transcriptional regulators of several non-neuronal lineages. Strikingly, gene ontology analysis of Myt1l-repressed targets showed enrichment of terms associated with several non-neuronal processes (such as cartilage, heart and lung development), suggesting that Myt1l can repress not only the fibroblast program but also additional non-neuronal programs (Extended Data Fig. 3e ). The gene expression signatures of MEFs, myocytes, hepatocytes and keratinocytes, but not of neurons, were strongly associated (odds ratio > 2) with repressed Myt1l target genes (Extended Data Fig. 3d, Supplementary Table 3 ). Remarkably, Myt1l motifs were depleted in promoters of neuronal compared to nonneuronal genes, whereas REST motifs were enriched to a similar extent in neuronal versus non-neuronal promoters (Extended Data Fig. 10h ). Finally, Myt1l strongly inhibited the formation of myocytes when overexpressed in primary myoblasts during differentiation or together with MyoD in fibroblasts ( Fig. 2f-h, Extended Data Fig. 4 ). The combination of these correlative and functional data suggests that the main physiological function of Myt1l is to repress many non-neuronal programs. Next, we investigated how Myt1l accomplishes transcriptional repression. To identify critical domains of Myt1l, we tested a collection of systematic Myt1l truncations that in combination with Ascl1 induced neuronal cell reprogramming assay (Fig. 3a, Supplementary Table 4 ). After ensuring that all Myt1l truncations were stable and localized to the nucleus, we found that a short, 423-amino-acid fragment was sufficient to generate mouse and human iN cells that were molecularly and functionally indistinguishable from those induced by full-length Myt1l ( Tables 1, 5 ). Thus, multiple DNA-interacting zinc-fingers are not required to engage DNA simultaneously but might simply increase the binding probability of Myt1l to its targets. Notably, downregulated Myt1l targets harbour significantly more AAGTT motifs than do upregulated targets, suggesting that binding affinity affects transcriptional output (Extended Data Fig. 3a) .
The N-terminal domain preceding the central zinc-finger cluster was also critical for Myt1l function, because increased truncation of this domain resulted in progressive loss of reprogramming activity ( Fig. 3a-d , Extended Data Fig. 5 ). As Myt1 family members have been reported to interact with Sin3b to mediate gene repression, we tested whether Myt1l can bind this repressive chromatin remodelling complex during neuronal reprogramming 14 . We found that both full-length Myt1l and Myt1l 200-623 , but not Ascl1 or Brn2, could enrich Sin3b by immunoprecipitation (Fig. 3f ). Sequence analysis revealed four highly conserved hydrophobic helical peptides within Myt1l 200-500 that are similar to reported Sin3-interacting domains (SIDs) known to bind the paired amphipathic helix of Sin3b 15 (Extended Data Fig. 8 ). To identify the SID of Myt1l we performed glutathione S-transferase (GST) pulldown experiments and found that the most N-terminal predicted SIDs were necessary and sufficient to bind Sin3b, while no fragment bound the p300 co-activator (Fig. 3g , Extended Data Fig. 8 ). ChIP-seq experiments showed that 80% of Myt1l targets, including the transcription factor Hes1, were co-bound by the repressive Sin3b-HDAC1 complex early during reprogramming (Fig. 3h, Extended Data Fig. 8c ). As expected, short hairpin RNA (shRNA)-mediated knockdown of Sin3b abolished iN cell formation, but this could also be due to additional roles of Sin3b 16 (Extended Data Fig. 8e-g ). Like its family member Myt1 17, 18 , Myt1l targets the Notch signalling pathway on multiple levels (Fig. 2c) . Notch signalling inhibits the differentiation of neural progenitor cells through Hes1-mediated repression of proneuronal factors such as Ascl1, but it remains unclear how newborn neurons escape this inhibition 19, 20 . We found that Myt1l largely inhibited the negative effect of Notch intracellular domain (NICD) on neuronal reprogramming and reduced the protein levels of Hes1 (Fig. 4a, b, Extended Data Fig. 9a ). Chemical inhibition of Notch using N-[N- (3,5- 
difluorophenacetyl)-l-alanyl]-S-phenylglycine
t-butyl ester (DAPT) enhanced Ascl1-mediated Tau-eGFP induction, but did not further enhance reprogramming induced by Ascl1 together with Myt1l (Extended Data Fig. 9b ). Combined overexpression of Ascl1 and Hes1 in MEFs not only counteracted neuronal reprogramming but also decreased Ascl1 levels without inducing neural stem-cell markers (Extended Data Fig. 9b, c) . Surprisingly, Hes1 overexpression decreased not only Ascl1 protein but also the transgenic Ascl1 mRNA, suggesting previously unrecognized post-transcriptional regulation of Ascl1 expression (Extended Data Fig. 9d ). Addition of Myt1l could not rescue the reprogramming block induced by Hes1 overexpression, whereas it could rescue the NICD-mediated reprogramming block, demonstrating that Myt1l-mediated Notch inactivation is primarily caused by direct repression of Hes1 transcription.
To investigate the physiological function of Myt1l during normal neurogenesis, we performed in utero electroporation of Myt1l-shRNA-GFP constructs into the forebrains of mice at E13.5. Myt1l depletion led to a substantial reduction in the number of electroporated cells in the cortical plate two days later, with a corresponding increase in GFP-positive cells in the ventricular and subventricular zones (Fig. 4e) . Moreover, we found a reduced fraction of Map2 + mature neuronal cells among GFP + cells, and there was a compensatory increase in GFP + apical (Sox2 + ) and basal (Tbr2 + ) progenitors, indicating that acute Myt1l depletion impairs neurogenesis in vivo (Fig. 4f-h ). Neural stem cells (NSCs) exhibit oscillatory Hes1 expression that triggers anti-phasic expression of proneural factors such as Ascl1 19 .
To test whether Myt1l could repress Hes1 and thereby trigger Ascl1 induction and neuronal differentiation, we overexpressed Myt1l 200-623 in mouse NSCs and observed increased neuronal differentiation (Fig. 4c, Extended Data Fig. 9f ). Western blot analysis of NSCs maintained in proliferating conditions with fibroblast growth factor (Fgf) and epidermal growth factor (Egf) showed that overexpression of Myt1l 200-623 strongly decreased Hes1 and slightly increased Ascl1 protein levels (Fig. 4d) . Remarkably, even exogenous Ascl1 Letter reSeArCH protein became stabilized upon Myt1l overexpression in MEFs during reprogramming, further suggesting that Hes1 also blocks Ascl1 post-transcriptionally (Extended Data Fig. 9e ). In summary, these findings show that Myt1l can render cells insensitive to Notch signalling and provide a molecular explanation of how newborn neurons can overcome the Notch anti-differentiation stimulus. Last, we investigated whether Myt1l also represses many nonneuronal programs in primary neurons. RNA-seq of cultured hippocampal neurons showed that shRNA-mediated Myt1l depletion led to de-repression of Myt1l target genes, such as Notch and Wnt pathway members, and overall induced gene ontology terms characteristic of non-neuronal tissues, including cartilage and heart (Extended Data  Fig. 10i, j) . Fibroblast-, keratinocyte-and hepatocyte-specific gene signatures were more highly enriched among induced than repressed genes (Extended Data Fig. 10g) . Importantly, the de-repression of non-neuronal programs was associated with loss of neuronal gene expression and functional properties (Extended Data Fig. 10a-f) . Moreover, sequence analysis showed that, in contrast to REST, Myt1l motifs are substantially depleted at neuronal gene promoters, further supporting the 'many-but-neuronal' repressive function of Myt1l (Extended Data Fig. 10h) .
In this study, we discovered a new kind of transcriptional repressor. Unlike conventional repressors that inhibit specific lineages, such as REST and Groucho, Myt1l appears to block a multitude of differentiation programs and lineage identities, but not the neuronal lineage. In combination with activating lineage master regulators such as Ascl1, the molecular repressor Myt1l acts in a perfect complementary fashion to enable cell fate determination. Similar pairs of activating and repressing transcription factors may yield optimal reprogramming for other lineages. Finally, our data suggest that the physiological function of Myt1l is to establish and maintain the identity of neurons. Myt1l is the only known transcription factor that is specifically expressed in all neurons throughout life, indicating that active repression of nonneuronal programs is critical for maintaining the neuronal identity 6 . It is possible that the various Myt1l mutations recently identified in autism, schizophrenia, major depression, and intellectual disability may affect the neuronal maintenance function of Myt1l rather than neurogenesis [21] [22] [23] [24] . If this were the case, it might provide the opportunity to carry out curative interventions even in adult patients.
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No statistical methods were used to predetermine sample size and the investigators were not blinded to allocation during experiments and outcome assessment. Reprogramming and efficiency calculation. Third-passage wild-type, heterozygous Tau-eGFP knock-in MEFs or human embryonic fibroblasts were infected with indicated lentivirus (available from us through Addgene or specified in Supplementary Table 4) in MEF medium containing 8 μ g/ml polybrene (Sigma) for 16-20 h. Cells were switched into fresh MEF medium containing 2 μ g/ml doxycycline (Sigma) to induce transgene expression for 2 days. On day 3 cells were switched into N3 medium (DMEM/F12) containing N2 supplement, B27, 20 μ g/ml insulin, penicillin/streptomycin (all from Invitrogen) and doxycycline to continue reprogramming. The medium was changed every 2-3 days for the duration of the reprogramming. To calculate the efficiency of neuronal induction, the total number of Tau-eGFP-and/or TUJ1-expressing cells with complex neurite outgrowth (cells having a spherical cell body and at least one thin process three times the size of their cell body) was counted manually 7 or 14 days after transgene induction by immunofluorescence microscopy. To calculate the efficiency of myocyte-like cell induction, the total number of desmin-and Myh-expressing cells was counted manually 14 days after transgene induction by immunofluorescence microscopy. The quantification was based on the average number of neuronal or myocyte-like cells present in a minimum of 30 randomly selected 20× fields of view from at least three biological replicates. The number of reprogrammed cells was then normalized either to the number of reprogrammed cells in the control condition or to the total number of cells determined by DAPI staining. Tau-eGFP-expressing cells in Fig. 4a and Extended Data Fig. 9b were quantified using a LSRFortessa fluorescence-activated cell analyser (BD Biosciences), on the basis of the average number of TauEGFP-positive cells detected in 60,000-120,000 analysed cells from at least three to six biological replicates. In utero electroporation. All animal protocols have been IRB approved by Stanford University. For in utero electroporation, pregnant CD-1 mice (Charles River) were deeply anaesthetized with isoflurane (Henry Schein), after which the uterine horns were carefully exposed through a midline abdominal incision. pSico constructs encoding both GFP and indicated shRNA-oligos from the same DNA plasmid (1-2 μ l of 2 μ g/μ l) were diluted in PBS containing 0.01% fast green (Sigma) as a tracer and injected in utero into the lateral ventricle of mouse embryos at E13.5 using a micropipette made from G-1 glass capillaries (Narishige). After injection, the embryo in the uterus was placed in a 5-mm platinum tweezertrode and five 50-ms square pulses of 25 V with 950-ms intervals were applied with an ECM 830 electroporation system (both from Harvard Apparatus). We performed randomized electroporations of control or Myt1l-targeting shRNAs in the right and left uterine horns of several pregnant mice to avoid any technical effect on the experimental outcome. Then, uterine horns were placed back into the abdominal cavity, and the abdominal wall of the pregnant mouse was sutured. Embryonic brains were harvested and dissected 2 days (E15.5) after electroporation for subsequent immunofluorescence processing and analysis. Brain sections were then co-stained with the indicated antibodies and anti-GFP to identify electroporated cells expressing the indicated knockdown constructs. The distribution of GFPpositive cells in each layer and the fraction of GFP and marker double-positive cells were determined by dividing the number of GFP-positive cells in each layer or the total number of double-positive cells by the total number of GFP-positive cells in the entire section, respectively. Electrophysiology. Electrophysiological recordings were performed from mouse primary hippocampal neurons 14 days after in vitro culture and 11 days after shRNA infection or on MEF-derived induced neuronal (MEF-iN) cells 21 days after transgene induction and 14 days after co-culturing on glia, following previous protocols 9 . In brief, action potentials were recorded using a current-clamp configuration with pipette solution containing (in mM): 130 KMeSO 3 , 10 NaCl, 2 MgCl 2 , EGTA 0.5 (for MEF-iN), 1 (for primary cultures), CaCl 2 0.16 (for MEF-iN), 0.1 (for primary cultures), 4 Na 2 ATP, 0.4 NaGTP, 14 Tris-creatine phosphate, and 10 HEPES-KOH (pH adjusted to 7.3, 310 mOsm). The bath solution contained (in mM): 140 NaCl, 5 KCl, CaCl 2 2 (for MEF-iN), 3 (for primary cultures), 1 MgCl 2 , 10 glucose, and 10 HEPES-NaOH (pH 7.4). Membrane potentials were kept around − 60 mV using small holding currents, and step currents were injected to elicit action potentials. Recordings of the intrinsic and active membrane properties were performed in the presence of 50 μ M picrotoxin, 10 μ M CNQX and 50 μ M d-AP5 in the bath solution (all from Tocris). The synaptic current recordings were performed in voltage-clamp mode with internal solution containing (in mM): 135 CsCl 2 , 1 EGTA, 4 Na 2 ATP, 1 Na-GTP, 1 QX-314, and 10 HEPES-NaOH (pH adjusted to 7.4, 310 mOsm). α -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor excitatory postsynaptic currents (EPSCs) were pharmacologically isolated by application of 50 μ M picrotoxin, and were subsequently blocked by addition of 50 μ M CNQX. Evoked synaptic responses were triggered by 1-ms, 1-mA current injection through a local extracellular electrode (FHC concentric bipolar electrode) with a Model 2100 Isolated Pulse Stimulator (A-M Systems). All recordings were performed in whole-cell configuration using a Multiclamp 700B amplifier (Molecular Devices). All average data were analysed from three or more biological replicates using Clampfit 10.4 (Axon Instruments). Cell line generation and maintenance. MEFs were isolated from wildtype or heterozygous Tau-eGFP knock-in mouse embryos at E13.5 (Jackson Laboratories) after removal of all neural cell-containing tissues. Mouse glial cells were isolated from forebrains of wild-type mice (Jackson Laboratories) at postnatal day 2. Both cell types were maintained in MEF medium (DMEM; Invitrogen) containing 10% cosmic calf serum (CCS; Hyclone), betamercaptoethanol (Sigma), non-essential amino acids, sodium pyruvate and penicillin/ streptomycin (all from Invitrogen) and passaged three times before experiments. Mouse NSCs were isolated from forebrains at E13.5 or cortex at E14.5 of wild-type mouse embryos. The cells were maintained on PO-laminincoated tissue culture dishes or as neurospheres in proliferation medium (DMEM/F12) containing N2 or B27 supplement, penicillin/streptomycin (all from Invitrogen), and 20 ng/ml Egf, 10 ng/ml Fgf (both from Peprotech). Cells were infected and kept in proliferation medium for 7 days after transgene induction using doxycycline or changed 1 day after infection to N3 medium (DMEM/F12) containing N2 supplement, B27, 20 μ g/ml insulin, penicillin/ streptomycin (all from Invitrogen), 1% fetal bovine serum (FBS; Hyclone), and doxycycline to induce differentiation for 7 days. For primary neuronal cultures, the hippocampus of P0 wild-type mouse pups was isolated and cultured on Matrigelcoated plates (Corning) in MEM supplemented with B27, glucose, transferrin and 5% FBS. Two days after plating, the medium was supplemented with 2 mM Ara-C (Sigma) as described previously 26 . Primary myoblasts were isolated and cultured on collagen-coated plates (Corning) in DMEM supplemented with 20% FBS and penicillin/streptomycin (Invitrogen) as described 27 . One day after infection and transgene induction using doxycycline, primary myoblasts were transferred into DMEM containing penicillin/streptomycin and 5% horse serum (all from Invitrogen) to induce muscle differentiation for 4 days. The medium for all cells was changed every 2-3 days for the duration of the experiment and all cells were grown at 37 °C and 5% CO 2 . Cells tested negative for mycoplasma contamination. Virus production and infection. Lentiviruses were produced by transfection of lentiviral backbones containing the indicated transgenes together with third-generation packaging plasmids into HEK293 cells following the Trono laboratory protocol 28 . Viruses were concentrated from culture supernatant by ultra-centrifugation (23,000 rpm, 2 h, 4 °C) and cells were infected with three different viral titres. Infected cell populations that were used for reprogramming and genomic analysis were verified by immunofluorescence to contain approximately 70-90% transgene-positive cells 2 days after induction by immunofluorescence microscopy. Plasmid constructs. DNA constructs were generated by PCR amplification with Phusion polymerase followed by restriction digest using the indicated enzymes and ligation with T4 DNA ligase (all from NEB). Site-directed mutations of Myt1l zinc-fingers 2-3 were generated using the QuikChange Multi Site-Directed Mutagenesis Kit (Agilent Technologies) following the manufacturer's instructions. A complete list of all constructs and primers generated in this study can be found in Supplementary Tables 4 and 6 . Protein expression and purification. Proteins for immunization and GST pull downs were expressed in E. coli Rosetta DE3 (Novagen). All His-and His-GSTtagged Myt1l fragments were purified under native conditions using Ni-NTA Agarose (Qiagen) and eluted in bacterial lysis buffer containing (in mM): 20 Tris pH 7.5, 500 NaCl, 1 MgCl 2 supplemented with 400 imidazole (all from Sigma). Eluted proteins were dialysed overnight against phosphate buffered saline (PBS) and supplemented with 10% glycerol (both from Sigma) before use or storage at − 80 °C. Antibodies. Polyclonal antibodies against Myt1l were raised in rabbits using recombinant His-tagged mouse mmMyt1l amino acids 171-420. Immune sera were affinity purified against the antigen immobilized on Affigel (Bio-rad) and eluted in buffer containing (in mM): 100 glycine pH 2.7, 150 NaCl followed by 100 glycine pH 2.2, 150 NaCl. 50 ml anti-Ascl1 hybridoma supernatant, 2.5 mg affinity purified anti-Myt1l antibody, and mouse or rabbit control IgG (Sigma) were each coupled to 250 μ l protein A sepharose (GE Healthcare) using buffer containing (in mM): 20 dimethyl pimelimidate in 200 Na 2 B 4 O 7 pH 9, blocked with 1,000 Tris pH 8, followed by 200 ethanolamine pH 8, washed with 200 Na 2 B 4 O 7 pH 9, washed with 200 glycine pH 2.2, 150 NaCl, and finally washed extensively using PBS (all from Sigma). A complete list of all primary antibodies used in this study can be found in Supplementary Table 7 . Secondary Alexa-conjugated antibodies were used at 1:2,000 (all from Invitrogen), secondary HRP-conjugated antibodies were used at 1:5,000 (all from Jackson Immunoresearch) and secondary IRDye-conjugated antibodies were used at 1:5,000 (all from LI-COR).
Immunofluorescence. Cultured cells were washed with PBS and fixed using 4% paraformaldehyde (PFA; Affymetrix) for 10 min. Cells were then permeabilized in 0.5% Triton X-100 (Sigma) in PBS for 5 min, blocked in a solution of PBS containing 2% bovine serum albumin (BSA; Sigma) for 1 h, and incubated with primary antibody for 1 h at room temperature or overnight at 4 °C. Cells were washed three times for 15 min using blocking solution before being incubated for 30 min with secondary antibodies. For DNA staining, 100 ng/ml DAPI was added to the last washing step (Invitrogen). Embryonic mouse brains were dissected and immersion fixed in 4% PFA overnight; adult mice were transcardially perfused first with PBS followed by ice-cold 4% PFA, then the brains were isolated and post-fixed in 4% PFA overnight. After fixation, embryonic and adult brains were cryoprotected overnight in 30% sucrose in PBS. Embryonic brains were embedded in OCT compound (Sakura), frozen in dry ice, sectioned on a cryostat at 20 μ m and mounted on glass slides. Adult brains were sectioned at 40 μ m using a freezing sliding microtome. For immunofluorescence, mounted (embryonic) or freefloating (adult) sections were washed in potassium phosphate buffer (KPBS). They were then incubated in KPBS with 0.25% Triton-X100 and 5% normal donkey and goat serum (pre-incubation solution; both from Jackson Immunoresearch) for 1 h at room temperature and incubated with primary antibody in pre-incubation solution overnight at 4 °C. Following washes in KPBS with 0.25% Triton-X100, sections were incubated with secondary antibodies and Hoechst (Invitrogen) in pre-incubation solution for 2 h at room temperature. After final washes in KPBS, free-floating sections were mounted on gelatin-coated slides and sealed using glycerol-based mounting medium. Microscopy images were obtained using a DM6000 B microscope equipped with a 20 × HCX PL air objective (NA 0.4) and a DFC365 FX digital camera (all from Leica). Immunoprecipitation experiments. For each immunoprecipitation, 20 × 10 6 MEF cells infected with the indicated transgenes 2 days after induction were lysed in 1 ml cell lysis buffer containing (in mM): 0.5% Tween-20, 50 Tris pH 7.5, 2 EDTA, 1 DTT, 1 PMSF, 5 NaF (all from Sigma), and complete protease inhibitor (Roche) for 15 min at 4 °C. Nuclei were pelleted by centrifugation (3,200 rpm, 1 min, 4 °C) and resuspended in 1 ml NP-40 lysis buffer containing (in mM): 0.5% NP-40, 50 Tris pH 8, 150 NaCl, 2 EDTA, 1 DTT, 1 PMSF, 5 NaF, 5 μ g/ml cytochalasin B (all from Sigma), complete protease inhibitor (Roche), and benzonase (Merck). Debris was removed by centrifugation (14,000 rpm, 10 min, 4 °C) and nuclear lysate was pre-cleared by incubation with 15 μ l uncoupled protein A beads before addition of 15 μ l antibody-coupled beads for 2 h at 4 °C. After binding, the beads were washed extensively in NP-40 lysis buffer and bound proteins were eluted with SDS-PAGE sample buffer. GST pull-down experiments. For each pull-down, 20 × 10 6 MEF cells were lysed in 1 ml cell lysis buffer containing (in mM): 0.5% Tween-20, 50 Tris pH 7.5, 2 EDTA, 1 DTT, 1 PMSF, 5 NaF (all from Sigma), and complete protease inhibitor (Roche) for 15 min at 4 °C. Nuclei were pelleted by centrifugation (3,200 rpm, 1 min, 4 °C) and resuspended in 0.5 ml cell lysis buffer containing 500 mM NaCl, 5 μ g/ml cytochalasin B (Sigma), and benzonase (Merk). Debris was removed by centrifugation (14,000 rpm, 10 min, 4 °C) and nuclear lysate was diluted with cell lysis buffer 1:1.25 (200 mM NaCl c.f.). 50 μ g of GST alone or GST-tagged Myt1l fragments were incubated with 20 μ l glutathione sepharose 4B beads (GE Healthcare) in PBS supplemented with 2 μ g/ml BSA (Sigma) and complete protease inhibitor (Roche) for 1 h at 4 °C. Beads were then washed extensively in cell lysis buffer containing 200 mM NaCl before addition of diluted nuclear lysate and incubation for 2 h at 4 °C. After binding the beads were washed extensively in cell lysis buffer containing 200 mM NaCl, and bound proteins were eluted with SDS-PAGE sample buffer. ChIP-seq and computational analysis. For each ChIP-seq experiment, either four brains from wild-type E13.5 mouse embryos or 20-40 × 10 6 primary cells 2 days after transgene induction were cross-linked using 1% formaldehyde (EMS) for 10 min followed by lysis in 1 ml swelling buffer containing (in mM): 0.5% NP-40, 5 HEPES pH 7.9, 85 KCl, 1 DTT, 1 PMSF (all from Sigma), and complete protease inhibitors (Roche) for 20 min on ice. Nuclei were pelleted by centrifugation (3,200 rpm, 1 min, 4 °C) and lysed in 1 ml lysis buffer containing (in mM): 1% SDS, 50 Tris pH 8, 10 EDTA, 1 DTT, 1 PMSF (all from Sigma), and complete protease inhibitors (Roche) for 10 min on ice. Chromatin was sheared using a Bioruptor sonicator (Diagenode) until DNA was fragmented to 200-500 bp followed by 1:4 dilution with buffer containing (in mM): 1% Triton X-100, 20 Tris pH 8, 2 EDTA, 150 NaCl, 1 PMSF (all from Sigma), and complete protease inhibitors (Roche). Diluted lysate was pre-cleared by incubation with 15 μ l Staph A cells or 50 μ l protein A beads before addition of antibody (20 μ g Sin3b or 50 μ g HDAC1) or 50 μ l antibody-coupled beads (Myt1l) overnight at 4 °C. After binding, the antibody-coupled beads were washed extensively in wash buffer containing (in mM): 1% NP-40, 0.05% SDS, 20 Tris pH 8, 250 NaCl, 2 EDTA (all from Sigma), and complete protease inhibitors (Roche). The reactions with uncoupled antibody were supplemented with 15 μ l Staph A cells washed extensively in the following three wash buffers containing (in mM): 1% Triton X-100, 0.1% SDS, 20 Tris pH 8, 150 NaCl, 2 EDTA; 1% Triton X-100, 0.1% SDS, 20 Tris pH 8, 500 NaCl, 2 EDTA; and 1% NP-40, 1% DOC, 10 Tris pH 8, 250 LiCl, 1 EDTA. After washing, the bound fraction was eluted in 100 μ l elution buffer containing (in mM): 1% SDS, 50 Tris pH 8, 10 EDTA, 100 PMSF and reversed cross-linked by overnight incubation at 65 °C. The isolated DNA was RNase (NEB) treated and purified using QIAGEN columns. Libraries were generated using the NEBNext ChIP-seq Library Prep Master Mix Set for Illumina (NEB) and single-end sequencing reads (50 bp) were generated on HiSeq 2500 platforms (Illumina). ChIP-seq reads are available on NCBI GEO under accession number GSE72121. Raw reads were mapped to mouse reference genome GRCm38/mm10 using bowtie2 (version 2.2.3) and allowing a maximum of one mismatch 29 . Peaks for each sample were called using MACS2 algorithm (version 2.0.10.20131216) 30 using the shift size values calculated from the run_spp.R script from the SPP peak caller 31 . High quality peaks were identified using IDR2 (https://github.com/nboley/idr). A negative control ChIP was performed as described above using the Myt1l antibody on rtTA-only infected cells. Any rtTA peak that overlapped a peak in any other condition by greater than 50% was excluded from the final analyses. Heatmaps of ChIP-seq signals were generated around peak summits (± 2 kb region) using 25-bp sliding windows with the HOMER suite (version 4.7) 32 . Read histograms, motif analysis, peak annotation, and gene ontology analysis were also performed using HOMER and PHANTER 33 . Both Bedtools and SAMtools were used for file processing and format conversions 34, 35 . Differential Myt1l localization was determined using the DiffBind R package 36 . All ChIP-seq data were analysed from two or three biological replicates. MNase-seq analysis. To assess nucleosome occupancy at candidate regions, we used a previously reported MEF MNase-seq data set (GSE40896) 25 . The raw reads were mapped to GRCm38/mm10 using bowtie (version 1.1.1) allowing one mismatch as described 37 . Histograms of read densities for the Myt1l peaks and Ascl1 peaks 8 (lifted over to mm10) were compiled using HOMER. Transcript analysis using RNA-seq and quantitative PCR. RNA was isolated using Trizol (Invitrogen) and treated with DNase (NEB). For RNA-seq, libraries were prepared following the dUTP protocol 38 and paired-end sequencing reads (100 bp) were generated on HiSeq 2500 platforms (Illumina). RNA-seq reads are available on NCBI GEO under accession number GSE72121. Raw reads were mapped to mouse reference genome GRCm38/mm10 using TopHat2 (version 2.0.10) 39 and transcript assembly and differential expression determined using cufflinks (version 2.1.1) according to the cuffquant pipeline 40 . CummeRbund was used to generate expression scatterplots and cluster3 and treeview were used to generate heatmaps [41] [42] [43] . GSEA was performed using all genesets in the MsigDB database (GSE14012) 44, 45 , including a MEF gene signature that was compiled by taking the genes that were enriched by a factor of 10 in the MEF condition compared to the induced neuronal condition from the raw RNA-seq data in ref. 8 Table 3 ). The significance of GSEA profiles was determined by an FDR < 0.25, as described 45 . Cell-type-specific gene signatures were derived from the top 10% of the genes unique to a particular cell type [46] [47] [48] [49] , excluding any genes common amongst four out of five sets to exclude housekeeping genes (Supplementary Table 3 ). Odds ratio analysis was performed using the GeneOverlap R package (version 1.6.0) 50 . For quantitative PCR, RNA was reverse transcribed using Superscript II (Invitrogen) following the manufacturer's instructions. Quantitative real time PCR was performed from cDNA templates using the SYBR Green PCR master mix and a 7900HT Fast Real-Time PCR System (Applied Biosystems). Transcript levels were determined after normalization against GAPDH using the Relative Expression Software Tool (REST) 51 . A complete list of real-time PCR primers used in this study can be found in Supplementary  Table 6 . All RNA-seq data were analysed from two biological replicates. SELEX. Constructs encoding Myt1l DNA-binding domains were generated by gene synthesis (codon optimized, Genscript) as indicated in Supplementary Table 5 . Clones were transferred to an N-terminal thioredoxin hexahistidine bacterial expression vector (pETG-20A-SBP; ref. 52 ) by a Gateway LR reaction (Invitrogen). Proteins were produced in the E. coli Rosetta DE3 pLysS (Novagen), and purified, and HT-SELEX analyses were performed as described previously 53 . After each SELEX cycle, the selection ligands were sequenced using HiSeq 2000 platforms (Illumina), and PWM models generated using the seed, cycle and multinomial model reported in Supplementary Table 5 as described here 53 . Data availability statement. ChIP and RNA-seq data have been deposited in the NCBI GEO database under accession number GSE72121. All other data are available from the corresponding author upon reasonable request. Names and annotated functions of tested genes are indicated, expression levels were normalized to Ascl1-only induction and GAPDH expression, n = 4 biological replicates (with 2 technical replicates each). Error bars show s.e.m., pair wise fixed reallocation randomization test * P < 0.001 (ref. 51) . c, Myt1l ChIP-seq profile at the Hes1 and Ncam1 promoter shows strong binding of endogenous Myt1l in E13.5 mouse brain and overexpressed wild-type Myt1l in MEFs two days after reprogramming; red bars mark multiple Myt1l AAGTTT motifs present in repressed Hes1 promoter and gene body. d, Overlap of Myt1l-bound target genes that are induced or repressed during conversion of MEFs into iN cells upon overexpression of Myt1l with or without Ascl1 and Brn2 and indicated cell type-specific expression signatures determined by GeneOverlap 50 . Odds ratio > 2 represents strong association, P values are shown in brackets; n.s., not significant. e, Selected top gene ontology (GO) terms of Myt1l-targeted genes that are repressed (top) or induced (bottom) during reprogramming determined by PANTHER 33 . Enrichment scores and P values are shown. Highlighted are the terms 'negative regulation of neuron differentiation' (green) in the repressed cluster and 'generation of neurons' (red) in the induced cluster. Both analyses show a striking enrichment of repressed Myt1l target genes within several non-neuronal programs. Of note, several metabolic GO terms are among the upregulated target genes.
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